Inovio Pharmaceuticals Inc
NASDAQ:INO

Watchlist Manager
Inovio Pharmaceuticals Inc Logo
Inovio Pharmaceuticals Inc
NASDAQ:INO
Watchlist
Price: 2.12 USD -2.3% Market Closed
Market Cap: 77.7m USD

Intrinsic Value

INO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one INO stock under the Base Case scenario is 20.59 USD. Compared to the current market price of 2.12 USD, Inovio Pharmaceuticals Inc is Undervalued by 90%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

INO Intrinsic Value
20.59 USD
Undervaluation 90%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Inovio Pharmaceuticals Inc

Valuation History Unavailable

Historical valuation for INO cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about INO?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Inovio Pharmaceuticals Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Inovio Pharmaceuticals Inc

Current Assets 71.9m
Cash & Short-Term Investments 68.4m
Receivables 1.3m
Other Current Assets 2.2m
Non-Current Assets 15.4m
Long-Term Investments 2.3m
PP&E 11.1m
Other Non-Current Assets 2m
Efficiency

Free Cash Flow Analysis
Inovio Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Inovio Pharmaceuticals Inc

Revenue
283.1k USD
Operating Expenses
-106.2m USD
Operating Income
-106m USD
Other Expenses
9.5m USD
Net Income
-96.5m USD
Fundamental Scores

INO Profitability Score
Profitability Due Diligence

Inovio Pharmaceuticals Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
Declining ROIC
12/100
Profitability
Score

Inovio Pharmaceuticals Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.

INO Solvency Score
Solvency Due Diligence

Inovio Pharmaceuticals Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
43/100
Solvency
Score

Inovio Pharmaceuticals Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

INO Price Targets Summary
Inovio Pharmaceuticals Inc

Wall Street analysts forecast INO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for INO is 8.16 USD with a low forecast of 2.02 USD and a high forecast of 13.65 USD.

Lowest
Price Target
2.02 USD
5% Downside
Average
Price Target
8.16 USD
285% Upside
Highest
Price Target
13.65 USD
544% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for INO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

INO Insider Trading
Buy and sell transactions by insiders

INO News

Other Videos
What is the Intrinsic Value of one INO stock?

The intrinsic value of one INO stock under the Base Case scenario is 20.59 USD.

Is INO stock undervalued or overvalued?

Compared to the current market price of 2.12 USD, Inovio Pharmaceuticals Inc is Undervalued by 90%.

Back to Top